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Background: Insulin signaling is tightly controlled by tyrosine dephosphorylation of the insulin receptor through
protein-tyrosine-phosphatases (PTPs). DEP-1 is a PTP dephosphorylating tyrosine residues in a variety of receptor
tyrosine kinases. Here, we analyzed whether DEP-1 activity is differentially regulated in liver, skeletal muscle and
adipose tissue under high-fat diet (HFD), examined the role of DEP-1 in insulin resistance in vivo, and its function in
insulin signaling.
Results: Mice were fed an HFD for 10 weeks to induce obesity-associated insulin resistance. Thereafter, HFD mice
were subjected to systemic administration of specific antisense oligonucleotides (ASOs), highly accumulating in
hepatic tissue, against DEP-1 or control ASOs. Targeting DEP-1 led to improvement of insulin sensitivity, reduced
basal glucose level, and significant reduction of body weight. This was accompanied by lower insulin and leptin
serum levels. Suppression of DEP-1 in vivo also induced hyperphosphorylation in the insulin signaling cascade of
the liver. Moreover, DEP-1 physically associated with the insulin receptor in situ, and recombinant DEP-1
dephosphorylated the insulin receptor in vitro.
Conclusions: These results indicate that DEP-1 acts as an endogenous antagonist of the insulin receptor, and
downregulation of DEP-1 results in an improvement of insulin sensitivity. DEP-1 may therefore represent a novel
target for attenuation of metabolic diseases.
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Antisense oligonucleotides, Metabolic tissues, Insulin signaling, Insulin receptor, ObesityLay abstract
Insulin resistance represents a main factor contributing to
type 2 diabetes in obese patients. The tremendous increase
of type 2 diabetes has developed to a world-wide epidemic
burden. However, the cellular mechanisms underlying
insulin resistance are only partly understood. There-
fore, a better understanding of the pathophysiology and
the molecular background of insulin resistance are highly
warranted. Several studies have described an increased* Correspondence: Kai.Kappert@charite.de
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reproduction in any medium, provided the orprotein-tyrosine-phosphatase activity in metabolic tissues
in obesity. Indeed, certain protein-tyrosine-phosphatases
are known to target the insulin receptor and negatively
regulating the insulin signaling pathway. We observed
that the activity of density-enhanced phosphatase-1
(DEP-1), a receptor-like transmembrane protein-tyrosine-
phosphatase, is upregulated in obese insulin resistant
mice. Additional studies showed the capacity of DEP-1 to
dephosphorylate the insulin receptor. Furthermore, redu-
cing DEP-1 by a pharmacological approach in mice im-
proved insulin sensitivity, reduced basal glucose level, and
led to lower body weight. Moreover, as shown in liver
tissues, DEP-1 physically associated with the insulinLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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phatase DEP-1 as novel component in insulin signal-
ing, and molecular target for the treatment of insulin
resistance and obesity-associated diseases.
Background
Obesity represents a significant health problem with epi-
demic proportions worldwide. Obesity-related insulin re-
sistance is fundamentally linked to development of type
2 diabetes, with critical impact on hypertension, athero-
sclerosis, and hyperlipidemia [1]. Thus, novel treatment
regimens are desired to face this enormous health bur-
den, and to decrease morbidity/mortality in insulin re-
sistant obese patients.
Insulin resistance is characterized by reduced glucose
uptake, metabolism, or storage, and impaired suppres-
sion of hepatic glucose output. The activity of the insulin
receptor kinase, a receptor tyrosine kinase (RTK), is de-
termined by the phosphorylation status, and is tightly
regulated by protein-tyrosine-phosphatases (PTPs) [2].
Thereby, PTPs inhibit postreceptor signaling in insulin-
responsive tissues such as adipose tissue, muscle, and
the liver. So far, 38 so-called “classical PTPs” have been
identified in the human genome, which all share a
catalytic signature motif V/I H C S X G. These PTPs
represent one subgroup of phosphatases with strict
tyrosine-specificity [3]. PTP activity has been described
to be dynamically enhanced in obesity in insulin-
sensitive tissue (adipose tissue, skeletal muscle and
liver) [4], with significant reduction after weight loss
[5,6]. So far, various PTPs were identified targeting the
insulin receptor kinase: PTP1B, SHP-1, SHP-2, CD45,
LAR, PTPalpha, and PTPepsilon [7-9]. Thus, efforts
have been undertaken to dissect the role of PTPs in in-
sulin signaling and metabolic diseases.
In particular, PTP1B has been studied as potential
therapeutic drug target in obesity and insulin resistance,
since genetic interruption resulted in resistance to high-
fat diet-induced insulin resistance and obesity [9,10].
Those PTP1B-deficient mice were characterized by in-
creased phosphorylation of the insulin receptor in both
liver and muscle tissue upon insulin challenge, as com-
pared to wild-type mice [9]. Furthermore, in vitro data
demonstrated direct interaction of PTP1B with the insu-
lin receptor, leading to efficient dephosphorylation of
tyrosine residues [9,11]. In contrast, PTP1B inhibition
enhances insulin receptor signals [12,13]. Type 2 dia-
betic individuals have recently been shown to have
dysregulated PTP1B gene expression in the skeletal
muscle [2], giving evidence that PTP1B is also critically
involved in human pathology. Besides PTP1B, SHP-1
has attracted attention, since SHP-1 deficient mice were
characterized by improved insulin receptor signaling to
insulin receptor substrate-PI3K-Akt in liver and muscle[8]. Furthermore, inhibition of SHP-1 via adenoviral
gene transfer resulted in enhanced insulin receptor
tyrosine- as well as Akt (at serine 473) phosphorylation
in myocytes upon insulin stimulation [14]. Thus, PTP
inhibition might constitute a useful approach for treat-
ment/prevention of obesity-associated insulin resistance
and type 2 diabetes. However, with regard to PTP1B, de-
velopment of efficient antagonists has been hampered by
a variety of factors, including low selectivity and bioavail-
ability [15]. Antisense oligonucleotides (ASOs) could over-
come this burden and were shown to be effective in both
rodents and primates [13,16,17].
The density-enhanced phosphatase (DEP)-1 was ini-
tially described to contribute to the mechanism of con-
tact inhibition of cell growth [18]. Moreover, DEP-1 is
upregulated by protective nutrients [19], and plays a piv-
otal role in determining neointima formation upon vas-
cular injury [20]. It was shown that DEP-1 interacts with
a variety of RTKs, including the platelet-derived growth
factor (PDGF) receptor beta [21], and the hepatocyte
growth factor (HGF) receptor c-Met [22]. A potential
role of DEP-1 in insulin receptor signaling has not been
described. Here we speculated that, based on its binding
to various tyrosine residues in RTKs, DEP-1 may directly
or indirectly interfere with insulin receptor signaling.
First hints for such an involvement of DEP-1 were given
by positive dephosphorylating effects using an 18-amino
acid phosphopeptide corresponding to three insulin re-
ceptor kinase autophoshorylation sites using the catalytic
domain of DEP-1 [23]. Thus, the present study was done
to elucidate the role of DEP-1 in insulin signaling, in-
cluding its potential binding to the tyrosine phosphory-
lated insulin receptor, and to investigate the effects of
ASOs targeting DEP-1 (ISIS 285564) in a metabolic
high-fat diet-induced obesity model characterized by re-
duced insulin sensitivity.
Results
DEP-1 activity is increased in high-fat diet-induced
obesity
The tyrosine-phosphatase activity – pan-PTP activity – in
insulin sensitive tissues was analyzed in mice fed with
an LFD or HFD for 16 weeks. HFD mice exhibited a sig-
nificant increase in body weight (LFD = 28.8 ± 0.8 g vs.
HFD = 32.2 ± 0.5 g; P < 0.01). Based on previous data
showing differential regulation of PTPs in models of obe-
sity/insulin resistance, we analyzed PTP activity in mice
subjected to LFD or HFD. A significant increase of pan-
PTP activity was detected in liver (Figure 1A) and skeletal
muscle (Figure 1B) in HFD mice. Also in adipose tissue
pan-PTP activity was higher in HFD mice than in LFD
mice (Figure 1C), but did not reach statistical signifi-
cance. To dissect which individual PTPs were respon-
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Figure 1 Diet-induced obesity increased pan-PTP activity and DEP-1 activity in liver and skeletal muscle in mice. A-C: Pan-PTP activity
was determined in liver, skeletal muscle and adipose tissue by measuring dephosphorylation of a 32P labeled phosphopeptide in total lysates
from mice fed an LFD or HFD for 16 weeks. Pan-PTP activity in mice fed with LFD were set to 100%; (n = 10 per group). D-F: Dephosphorylation
of a 32P labeled phosphopeptide was measured for precipitated PTP1B and DEP-1 in LFD and HFD mice. Tissue lysates were subjected to
immunoprecipitation. PTP1B and DEP-1 activity in mice fed with LFD were set to 100%; (n = 5–6 per group). *P < 0.05, ***P < 0.001.
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immunoprecipitation. PTP1B, described as a negative
regulator in insulin signaling [9,10] and previously demon-
strated increased activity under HFD in metabolic tissues
[24], was compared to DEP-1 activity. Measurements
of the specific DEP-1 activity revealed a significant
upregulation in liver (Figure 1D) and skeletal muscle
(Figure 1E) under HFD. However, in the adipose tissue
no increase in PTP1B- and DEP-1 activity was detected
in HFD mice (Figure 1F). These results provide evi-
dence that DEP-1 is upregulated in diet-induced
obesity.
Reduction of DEP-1 expression and DEP-1 activity by
ASOs in high-fat diet-induced insulin resistant mice
Based on the increase in DEP-1 activity in diet-induced
obesity (Figure 1D-E) – measured under reduced condi-
tions – we hypothesized that DEP-1 plays a role in meta-
bolic changes and insulin signaling. Thus, HFD-fed mice
were treated with antisense oligonucleotides (ASOs)
against DEP-1 or control ASOs. To confirm successful
ASO application and subsequent attenuation of DEP-1
we analyzed the extent of DEP-1 suppression on transcript
level and DEP-1 activity. In HFD-fed mice treated with
ASOs targeting DEP-1, a significant reduction of mRNA
levels by ~46% in the liver (Figure 2A), and by ~38% in adi-
pose tissue (Figure 2C) was observed compared to control
ASO mice. Also in skeletal muscle a nonsignificant sup-
pression was observed (Figure 2B). However, “secondary
effects” may explain this unexpected reduction intranscripts in skeletal muscle, since ASOs are not consid-
ered to significantly distribute to skeletal muscle tissue
regulating target genes [25]. Analyzing PTP1B mRNA
levels revealed no compensatory regulation, and also insu-
lin receptor mRNA was not affected by DEP-1 suppression
in all tissues. Furthermore, DEP-1 activity was significantly
decreased in liver (Figure 2D) and skeletal muscle
(Figure 2E) after DEP-1 ASO treatment, while, surpris-
ingly, no reduction of DEP-1 activity was measured in adi-
pose tissue (Figure 2F) compared to control ASO mice.
In addition to DEP-1 mRNA transcription level and
DEP-1 activity we analyzed DEP-1 protein expression in
the liver by immunoblotting analysis (Figure 3A). We
detected a significant downregulation of DEP-1 in the
DEP-1 ASO group compared to control ASO treated
mice (Figure 3B), substantiating the DEP-1 mRNA and
DEP-1 activity measurements.
To exclude ASO effects per se on total tyrosine phosphor-
ylation levels we performed immunoblotting in liver tissue
derived from ASO-treated and untreated mice (Additional
file 1: Figure S1). This analysis did not show changes in liver
tyrosine phosphorylation due to ASO treatment.
Summarized, DEP-1 ASO administration resulted in
an effective reduction of DEP-1 transcripts, activity and
protein expression in liver of HFD-mice.
DEP-1 suppression improves metabolic parameters in
high-fat diet-treated mice
During the application period the body weight of control






























































































































































































Figure 2 Administration of DEP-1 antisense oligonucleotides (ASOs) reduced DEP-1 expression and activity in metabolic tissues. A-C:
Quantitative real-time PCR was performed for DEP-1, PTP1B and insulin receptor (IR) in liver, skeletal muscle and adipose tissue mRNA from mice
subjected to either control ASO or DEP-1 ASO treatment. Gene expression was normalized to expression of the housekeeping gene 18S and is
shown as mean ± standard error of the mean; (n = 8–9 per group). D-F: DEP-1 activity was measured using a dephosphorylation assay of a 32P
labeled phosphopeptide after immunoprecipitation of DEP-1 in liver, skeletal muscle and adipose tissue from mice subjected to either control
ASO or DEP-1 ASO treatment. DEP-1 activity in control ASO mice were set to 100%; (n = 6 per group). *P < 0.05, **P < 0.01, ***P < 0.001.
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cant reduction was observed in DEP-1 ASO animals
when compared to control ASO (Figure 4A). After five
weeks of ASO treatment the body weight difference be-
tween both groups was 1.5 g (control ASO 34.0 ± 0.7 g
and DEP-1 ASO 32.5 ± 0.5 g; P < 0.05), and independent
of mean food intake (Table 1). Additionally, in congru-
ence with the body weight loss, the weight of epididymalfat as well as perirenal fat was significantly reduced in
DEP-1 ASO treated mice, along with increased liver
weight (Table 1), which is in line with previous observa-
tions in PTP1B ASO mice [4,17]. In contrast, kidney and
heart weight remained unchanged.
Further, we analyzed whether energy metabolism pa-
rameters were affected in DEP-1 ASO mice by monitoring
animals over 18 hours in metabolic cages (LabMaster),
ADEP-1
GAPDH






















Figure 3 DEP-1 protein expression is reduced in the liver after antisense oligonucleotide (ASO) treatment. A: DEP-1 protein expression
was analyzed after wheat-germ-agglutinin (WGA) precipitation and visualized by immunoblotting of tissues derived from control ASO and DEP-1
ASO treated mice; (n = 4 per group). B: Densitometric analysis of immunoblotting data was performed after normalization to the housekeeping
protein GAPDH and expressed as arbitrary units; (n = 8–9 per group). **P < 0.01.
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http://www.biosignaling.com/content/11/1/49measuring food intake, water intake, cage temperature,
locomotor activity (Table 1) as well as respiratory ex-
change ratio (RER) (Table 1 and Figure 4B). A significant
difference in RER between both groups was detected, indi-
cating a shift to carbohydrate utilization in DEP-1 ASO
treated mice. Furthermore, cage temperature was signifi-
cantly higher in the DEP-1 ASO group, suggesting an im-
pact on thermogenesis. No significant difference between
DEP-1 ASO and control ASO treated mice was detected



















































































































Figure 4 Basic metabolic phenotyping of mice subjected to control A
twice weekly during the application period with ASOs; (n = 8–10 per group
metabolic cages (LabMaster). Each data point represents n = 8–9 animals p
performed 5 weeks after ASO administration by injection of 0.5 U insulin/kg
AUC to (C). E: After 6 weeks of ASO administration a glucose tolerance test
body weight quantified by AUC; (n = 8–9 per group). *P < 0.05, **P < 0.01.To address whether DEP-1 suppression led to im-
provement of insulin and glucose tolerance mice were
subjected to both intraperitoneal ITT and GTT. DEP-1
ASO treated mice showed improvement in insulin sensi-
tivity, with significant reduction in glucose levels at base-
line and 15 min after insulin injection compared to
control ASO mice (Figure 4C), also evidenced when the
area under the curve (AUC) was calculated (Figure 4D).
However, DEP-1 ASO treatment did not result in an im-
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SO and DEP-1 ASO administration. A: Body weight was monitored
). B: Respiratory exchange ratio (RER) was measured over 18 h in
er group. C: An intraperitoneal insulin tolerance test (ITT) was
body weight to fasted mice; (n = 7 per group). D: Corresponding
(GTT) was performed in fasted mice by injection of 1 g glucose/kg
Table 1 Metabolic phenotyping of control and DEP-1 ASO
treated mice
Control ASO DEP-1 ASO P-value
LabMaster analysis
Food intake [g] 1.7 ± 0.2 2.0 ± 0.1 0.230
Water intake [ml] 1.8 ± 0.2 2.1 ± 0.2 0.317
Temperature [°C] 20.379 ± 0.015 20.520 ± 0.018 < 0.001
Locomotor activity [x + y] 61426 ± 5246 53600 ± 4465 0.287




Epididymal fat 18.4 ± 1.7 13.8 ± 1.0 0.038
Perirenal fat 7.3 ± 0.8 5.1 ± 0.6 0.048
Liver 38.6 ± 1.7 51.8 ± 0.9 < 0.001
Heart 4.8 ± 0.3 4.3 ± 0.1 0.197
Kidney 11.3 ± 0.9 11.1 ± 0.5 0.830
Control ASO and DEP-1 ASO mice were characterized using metabolic cages
(LabMaster) 4 weeks after ASO treatment. Measurements of an 18 hours
period (12 am–6 am) are shown. Data were recorded every 15 min. After
sacrificing of mice, organs weights were determined. Data are shown as mean ±
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http://www.biosignaling.com/content/11/1/49improved insulin sensitivity, DEP-1 ASO treated mice also
showed significantly decreased fasting insulin and leptin
levels compared to control ASO mice (Figure 5A-B). In
contrast, adiponectin concentrations were not altered by



















Figure 5 DEP-1 ASO mice were characterized by improvement
in metabolic serum parameters. Fasting serum insulin (A), leptin
(B), and adiponectin levels (C) were determined by ELISA
measurements; (n = 6–9 per group). *P < 0.05.DEP-1 suppression leads to increased phosphorylation
levels in insulin signaling in vivo
Phosphorylation levels of key intermediates in insulin
signaling were analyzed in metabolic tissues by immuno-
blotting to investigate how DEP-1 suppression modu-
lates this signaling pathway. Analyses of control ASO
and DEP-1 ASO treated mice were done in animals
which were challenged with or without intraveneous in-
jection of insulin 2 min prior of sacrificing. In liver tis-
sues an increase of total tyrosine phosphorylation of the
insulin receptor after insulin administration was ob-
served in the DEP-1 ASO group compared to control
ASO mice (Figure 6A). Furthermore, the phosphoryl-
ation of Akt at sites Thr 308 and Ser 473 were increased
in DEP-1 ASO mice (Figure 6A) compared to control
ASO mice, suggesting further impact on downstream
signaling by DEP-1 suppression. In addition, densitomet-
ric analysis of insulin receptor phosphorylation and Akt
phosphorylation at sites Thr 308 and Ser 473 revealed a
significant increase after insulin challenge in DEP-1
ASO treated mice (Figure 6B-D). Phosphorylation levels
of insulin signaling intermediates in adipose tissue were
equal in both groups (data not shown), which is inaccordance that DEP-1 activity was unaffected by DEP-1
ASO treatment (Figure 2F). To substantiate the finding of
higher insulin receptor phosphorylation in DEP-1 ASO-
treated mice, liver sections were subjected to Proximity
Ligation Assays (PLA) using co-incubation of antibodies
directed against the insulin receptor and phosphotyrosine
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Figure 6 (See legend on next page.)
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Figure 6 Insulin signaling was enhanced in DEP-1 ASO mice. A: Immunoblotting analysis of liver lysates in control ASO or DEP-1 ASO treated
mice challenged with intraveneous injection of insulin (10 U/kg body weight, 2 min) prior to euthanasia; (n = 3 per group). Key intermediates of
the insulin signaling cascade were analyzed with indicated antibodies. GAPDH was used as the loading control. B-D: Densitometric analysis of
immunoblotting for pTyr 99 (normalization to IR), pAkt (Ser 473) and pAkt (Thr 308) (normalization to Akt) were performed and expressed as
arbitrary units; (n = 3 per group). *P < 0.05, **P < 0.01. E: Detection of phosphorylated insulin receptor in liver tissue of mice. Insulin receptor
tyrosine phosphorylation was detected by in situ PLA (red dots) applying anti-insulin receptor and anti-phosphotyrosine antibodies. Liver tissue
sections derived from C57BL/6J mice subjected to either control ASOs or DEP-1 ASOs and insulin stimulation, as described in A. The cells were
counterstained with DAPI (blue) to visualize the nuclei. Specificity of antibody binding and PLA method is demonstrated by control sections with
either only antibodies against the insulin receptor (IR), against phosphotyrosine (pY100), or omitting primary antibodies (none). Insets of
representative cells are shown. Scale bars represent 25 μm. F: The quantification of PLA signals per cell for animal groups is depicted as the
percentage of each population with a certain number of RCPs per cell (n = 424–458 cells per group).
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sine phosphorylation in DEP-1 ASO treated mice, as com-
pared to that observed in insulin-treated control ASO
mice, which is also demonstrated by a cell based quantifi-
cation in Figure 6F.DEP-1 is recruited to the insulin receptor upon insulin
stimulation in situ
Finally, after showing that DEP-1 was differentially regu-
lated in metabolic tissues in diet-induced obesity, and
that DEP-1 significantly impacts on insulin signaling, we
addressed whether DEP-1 physically associates with the
insulin receptor by recruitment studies applying PLA.
This in situ method is able to visualize protein interac-
tions at a resolution of ~40–50 nm. Figure 7A-B depicts
representative pictures of liver sections, and a cell-based
quantification, clearly demonstrating that DEP-1 is
recruited to close proximity of the insulin receptor upon
insulin stimulation.
Thus, these data support the notion that DEP-1 is a
negative regulator of insulin signaling at the level of the
insulin receptor, and may represent a novel target in in-
sulin resistance.DEP-1 dephosphorylates the insulin receptor
To substantiate the findings of DEP-1 recruitment to the
insulin receptor and hyperphosphorylation of the insulin
receptor upon DEP-1 ASO administration, we analyzed
the dephosphorylating capacity of DEP-1. AML12 liver
cells were stimulated with insulin and the insulin recep-
tor was subsequently immunoprecipitated following by
incubation with recombinant DEP-1. As shown in
Figure 7C, insulin-induced phosphorylation of the in-
sulin receptor at tyrosine residues was clearly reduced
by recombinant DEP-1. The dephosphorylation by DEP-1
was comparable to PTP1B, a phosphatase known to target
and dephosphorylate the insulin receptor. Furthermore,
inhibiting the phosphatase activity of both DEP-1 and
PTP1B restored the tyrosine phosphorylation level of the
insulin receptor. Taken together, DEP-1 exhibits insulin
receptor dephosphorylation capacity.Discussion
In this study we demonstrate for the first time that the
protein-tyrosine-phosphatase (PTP) DEP-1 is differen-
tially regulated in a model of high-fat diet (HFD) in-
duced obese mice, and that targeting DEP-1 leads to
improvement of the metabolic phenotype.
In detail, we report that the activity of DEP-1 is in-
creased in liver and skeletal muscle in HFD induced
obese mice. To further analyze the role of DEP-1 in diet-
induced obesity and in insulin signaling we applied DEP-
1 antisense oligonucleotides (ASOs). This therapeutic
approach with ASOs given to mice with reduced insulin
sensitivity, resulted in an altered metabolic phenotype
including reduced body weight, improved insulin sensi-
tivity, and higher respiratory exchange ratio along with
enhanced insulin signaling in liver. Moreover, we show
that the insulin receptor is being dephosphorylated by
recombinant DEP-1, and that DEP-1 is recruited into
close proximity of the insulin receptor upon receptor
ligation.
The activity of the PTPs PTP1B and SHP-1 [4,12] was
earlier shown to be increased in obesity states in mice
models. While DEP-1 was not previously described, the
current study shows increased DEP-1 activity in both
liver and skeletal muscle in obese animals. DEP-1 repre-
sents an ubiquitously expressed PTP interacting with
various receptor tyrosine kinases like EGF receptor
[26], HGF receptor [22], PDGF receptor [21], RET re-
ceptor [27], and VEGF receptor-2 [28]. DEP-1 is also
involved in modulation of distinct key cellular compo-
nents p85 [29], Akt/PKB [30] and Erk 1/2 [31], which
are part of the insulin signaling pathway. Thus, this
phosphatase may represent a therapeutic target of
HFD-induced obesity and metabolic disorders includ-
ing insulin resistance.
As expected, and shown earlier for other targets
[16,17,32], in our study administration of DEP-1 ASOs
lead to a significant reduction on DEP-1 transcript level
in liver and adipose tissue in mice fed an HFD. Further-
more, we also observed a nonsignificant reduction of
DEP-1 mRNA in the skeletal muscle correlating with a
decrease of DEP-1 activity in mice subjected to DEP-1
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Figure 7 Detection of the recruitment of DEP-1 to the insulin receptor. A: The recruitment of DEP-1 to the insulin receptor was detected by
using in situ PLA (red dots) in liver tissue sections of C57BL/6J mice which were either untreated or stimulated with insulin (10 U/kg body weight,
2 min). The cells were counterstained with DAPI (blue) to visualize the nuclei. Insets of representative cells are shown. Scale bars represent 25 μm;
none, no primary antibody; insulin receptor (IR), rabbit anti-IR antibody; DEP-1, goat anti-DEP-1 antibody. B: The quantification of PLA signals per
cell for both groups is depicted as the percentage of each population with a certain number of RCPs per cell (n = 350–500 cells). C: AML12 liver
cells were used for evaluation of insulin receptor dephosphorylation by PTPs. Starved cells were left resting (−) or were stimulated with 100 nM
insulin (+) for 10 min, followed by cell lysis and protein isolation. The immunoprecipitated insulin receptor was subjected to recombinant DEP-1
or PTP1B, as indicated, with or without preincubation with sodium vanadate (n = 3 experiments). Immunoblotting was performed with
depicted antibodies.
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this unexpected result, based on changes in serum pa-
rameters and metabolism metabolites, which may impact
on DEP-1 transcript levels leading to decreased DEP-1
activity in the skeletal muscle.
Furthermore, DEP-1 transcript levels were significantly re-
duced in adipose tissue, which did not translate into reduced
DEP-1 activity. This was in line with findings that phosphor-
ylation of key intermediates in insulin signaling was un-
affected (data not shown). Interestingly, Takahashi et al. [33]
recently reported binding of the newly identified DEP-1
ligand. Thrombospondin-1 was leading to increased DEP-
1 catalytic activity and consecutively to dephosphorylation
of substrate proteins. Thrombospondin-1, an adipokine
shown to be increased in adipose tissue [34], might coun-
teract the reduced DEP-1 transcript levels. Possibly, alsoinflammation factors secreted from adipose tissue affect
the expression/activity of DEP-1, as shown earlier for
PTP1B [24].
In addition to detection of lower DEP-1 transcript levels
and DEP-1 activity (determined under reduced condi-
tions), we performed immunoblotting analyses of precipi-
tated DEP-1. Our data clearly demonstrate both efficiency
and specificity of DEP-1 ASO treatment, since expression
of DEP-1 was reduced while gene expression of other in-
sulin signaling components was unchanged (PTP1B, insu-
lin receptor) in epididymal tissue, skeletal muscle, and
liver. Also additional PTPs (LAR, TC-PTP, SHP-2) were
not regulated in liver tissue (data not shown), underlining
specificity of the DEP-1 ASO used in our study. Further-
more, ASO treatment itself seems to have a neglectable
impact per se, since no significant changes were detectable
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derived from untreated (HFD) and HFD-fed ASO-treated
mice.
In general, DEP-1 ASO application leads to decreased
endogenous mRNA level and therefore reduced protein
and activity levels were detected, as we could show for
the liver tissue.
Metabolic phenotyping revealed changes in body com-
position, evidenced by a significant decrease in body
weight in mice receiving DEP-1 ASOs, along with a de-
crease in white fat pad mass in sacrificed mice. This lean
phenotype was associated with an increase in the re-
spiratory exchange ratio (RER). We and others have
reported low RER in diabetic rodents and under HFD
[35,36]. Both control ASO and DEP-1 ASO mice
exhibited low RER values. However, HFD-treated mice
subjected to DEP-1 ASO treatment were characterized
by significantly higher RER values at defined time points.
These data indicate augmented food metabolism towards
higher ratio of carbohydrate utilization. However, further
studies should focus on delineation of the underlying
mechanism of increased RER in combination of reduced
adipose tissue mass under HFD and PTP targeting
through ASOs.
In the current study we were able to show that DEP-1
ASO treatment improved insulin sensitivity. This is in
line with previous reports on ASO treatment targeting
PTP1B and LMW-PTP in rodent models, which lead to
beneficial impact on ITT [16,17]. The impact of DEP-1
ASOs on DEP-1 activity was only pronounced in liver
and skeletal muscle compared to adipose tissue. In con-
trast to the effects on insulin sensitivity, DEP-1 ASO ap-
plication did not produce detectable changes in glucose
tolerance. This may favor the hypothesis that DEP-1 ac-
tion in liver is more important than skeletal muscle ef-
fects, since glucose excursion in GTT is mainly
mediated by the skeletal muscle. This might partly ex-
plain the apparent diverse effects in insulin and glucose
tolerance.
The increased insulin sensitivity was accompanied by
decreased insulin levels after DEP-1 ASO treatment.
Further, leptin, an adipocyte secreted hormone, known
to be increased in HFD with concordant regulation of
adipose tissue growth [37], was reduced by DEP-1 ASOs,
reflecting the observed lower body fat accumulation and
decreased body weight. Adiponectin, a key player in
regulation of insulin sensitivity, was shown to be
upregulated after weight loss [38]. However, serum
adiponectin levels were not affected by DEP-1 ASO
treatment in our study. Interestingly, Christiansen et al.
[39] showed that diet-induced weight loss enhanced cir-
culating adiponectin, although exercise connected
weight loss improved insulin sensitivity without changes
in adiponectin level. Furthermore, possibly the extentand/or the time period of weight loss were not sufficient
to produce a detectable reduction in adiponectin levels
[40,41]. In addition, weight loss in our model maybe in
part related to changes in thermogenesis, suggested by
animal temperature differences assessed by LabMaster
analyses, or impact on genes involved in lipogenesis.
Targeting DEP-1 by ASOs improved not only systemic
effects including insulin sensitivity, but also insulin ac-
tion at cellular/tissue level in insulin signaling pathways.
Insulin-induced insulin receptor phosphorylation at
tyrosine residues, and phosphorylation of downstream
key components Akt Ser 473 and Akt Thr 308 was en-
hanced in liver, providing an additional molecular evi-
dence for the increased insulin sensitivity in vivo. These
data imply that DEP-1 acts as a regulator of the insulin
pathway through dephosphorylation of the insulin recep-
tor. However, we can not exclude whether further sub-
strates of DEP-1 in the insulin signaling pathway exist,
facilitating the enhanced signaling cascade [29,30]. Using
the proximity ligation assay we unraveled the recruit-
ment of DEP-1 into close proximity of the phosphorylated
insulin receptor. In addition to the enhanced phosphoryl-
ation of the insulin receptor upon DEP-1 ASO treatment,
these results indicate that the phosphorylated insulin re-
ceptor may serve as a substrate for DEP-1. This is also im-
plicated by showing dephosphorylation of the insulin
induced tyrosine-phosphorylated insulin receptor by re-
combinant DEP-1. However, no clear evidence for site-
selectivity of DEP-1 regarding the insulin receptor was
implicated in vitro (data not shown). This is in line with
the observation by Barr et al. [42], showing that DEP-1, in
contrast to other PTPs, is characterized by rather low
in vitro substrate specificity.
It is important to emphasize that this study identified
DEP-1 acting as a negative regulator in insulin signaling.
However, the role of DEP-1 as a tumor suppressor in a
number of epithelial cancers may not be neglected
[19,43]. Future experiments are required to delineate if
rather a tissue specific role of DEP-1 in metabolic tissues
regarding insulin/glucose/lipid metabolism is required to
improve safety. This may facilitate targeting DEP-1 in
metabolic diseases without impairment of DEP-1 as a
tumor suppressor protein, although neither spontaneous
tumors were observed during DEP-1 ASO treatment in
this study nor were described for DEP-1 KO mice [44].
Conclusions
To conclude, our results indicate for the first time that
targeting DEP-1 by using ASOs in mice exerts beneficial
metabolic effects, in particular with regard to the role in
insulin sensitivity and signaling. As a novel identified
negative regulator of insulin receptor signaling, DEP-1
represents a potential target for the treatment of insulin
resistance and type 2 diabetes.
Krüger et al. Cell Communication and Signaling 2013, 11:49 Page 11 of 14
http://www.biosignaling.com/content/11/1/49Methods
Animal model
Male C57BL/6J mice were purchased from Janvier (Le
Genest-Saint-Isle, France) at an age of 4 to 6 weeks.
Mice were housed at room temperature (25°C) with a
12 hours light/dark cycle and fed for 10 weeks ad libitum
with a low-fat diet (LFD) (n = 10) (10% kcal from fat;
Altromin, Lage, Germany) or high-fat diet HFD (n = 33)
(60% kcal from fat; Altromin, Lage, Germany). Afterwards
mice of both groups (LFD n = 10, HFD n = 15) were
treated with vehicle intraperitoneally for 6 weeks. Add-
itional HFD mice (n = 18) were randomly assigned in a
therapeutic approach to ASO treatment with control
ASOs 5′-CCTTCCCTGAAGGTTCCTCC-3′ (n = 8) (ISIS
141923) and DEP-1 ASOs 5′-TACATTGCTGCCATC
TCCAG-3′ (n = 10) (ISIS 285564) by injection intraperito-
neally twice a week for 6 weeks at a dose of 25 mg/kg
body weight. The used DEP-1 ASO sequence (ISIS
285564) was chosen based on initial ASO efficacy- and
comparison experiments in C57BL/6J mice. Noteworthy, a
chemically identical compound ASO (ISIS 141923) with-
out known complementarity to any known gene sequence
was used as a control ASO. Both ASOs were synthesized
as 20-base phosphorothioate chimeric ASOs, where
bases 1–5 and 16–20 had 2′-O-(2-methoxyethyl) modifi-
cation. Before animals were sacrificed insulin (10 U/kg)
(Insuman® Rapid, Sanofi Aventis, Berlin, Germany) was
injected intraveneously and allowed to circulate for 2 min.
Mice were killed under isoflurane anesthesia and organs
were excised, weighed, and shock-frozen in liquid nitrogen
and stored at −80°C until further use.
All animal procedures were in accordance with institu-
tional guidelines and were approved by the Landesamt
für Gesundheit und Soziales (LaGeSo, Berlin, Germany).
Metabolic phenotyping (body weight, LabMaster, GTT,
ITT, ELISA)
Body weight of all mice was measured twice a week
throughout the whole study. Food and water intake, re-
spiratory exchange ratio (RER), cage temperature, and
locomotor activity were measured using an indirect cal-
orimetry system (LabMaster, TSE Systems GmbH; Bad
Homburg, Germany). Mice were placed in the calorim-
etry systems for up to 24 hours. After adaptation periods
continuous measurements over 18 hours were used for
analysis. An intraperitoneal insulin tolerance test (ITT)
using a dose of 0.5 U/kg insulin (Insuman® Rapid, Sanofi
Aventis, Berlin, Germany) and a glucose tolerance test
(GTT) by intraperitoneal injection of 1 g/kg glucose
(Glucosteril, Fresenius, Bad Homburg, Germany) were
carried out in fasted mice. Tail vein blood was used for
measuring the glucose concentration with a glucometer
(Precision Xceed, Abbott, Wiesbaden, Germany) at dif-
ferent time points. Blood from mice was used tomeasure fasted serum insulin, leptin and adiponectin
concentration by ELISA according the manufacturer’s
instructions (Millipore, Schwalbach, Germany).
Protein-tyrosine-phosphatase activity
Metabolic tissues (liver, gastrocnemius skeletal muscle,
epididymal adipose fat tissue) were lysed in a dounce
homogenizer using lysis buffer adjusted to tissue weights
(150 mM NaCl, 25 mM C2H3NaO2, 1% NP-40, 10 mM
DTT, aprotinin (4 μg/ml)). Pan-PTP activity measure-
ments were performed by using crude cell lysate and re-
action buffer (25 mM imidazole pH 7.4, 10 mM DTT) in
a total volume of 50 μl, and DTT was added to a final
concentration of 50 mM. For immunoprecipitation PTP
analyses anti-DEP-1 and anti-PTP1B (AF1934 and
AF3954 R&D Systems, Wiesbaden, Germany) were used
at a concentration of 1 μg in an end-over-end reaction
at 4°C over night. Immunoprecipitates were collected by
Dynabeads® Protein G (Invitrogen, Karlsruhe, Germany)
for 1 hour. After washing two times with lysis buffer
and once with reaction buffer the precipitates were
resuspended in 50 μl reaction buffer, and DTT was added
to a final concentration of 50 mM. Pan-PTP activity and
specific PTP activity was determined using a 32P-labeled
src-optimal peptide as substrate. Measurements were
performed in duplicate, and phosphatase activity was de-
termined as the amount of 32P-labeled radioactivity re-
leased from the peptide after 7 min of incubation at 30°C.
Quantitative real-time PCR
RNA was isolated with RNeasy Mini Kit (Qiagen,
Hilden, Germany) following the manufacturer’s instruc-
tion for purification from cells and tissue (liver, skeletal
muscle, adipose tissue), and cDNA synthesis was done
with SuperScript®II (Invitrogen, Karlsruhe, Germany).
Quantitative real-time PCRs were performed with
SybrGreen (Applied Biosystems, Darmstadt, Germany)
in duplicate and the expression of analyzed genes was
normalized to the average expression of the housekeep-
ing gene 18S. Following primer sequences (at final con-
centrations of 100 nM) were used for gene expression
analysis: 18S fwd: 5′-GACTCTTTCGAGGCCCTGTA-3′
and rev: 5′-CACCAGACTTGCCCTCCAAT-3′; Insulin
receptor fwd: 5′-CAATGGGACCACTGTATGCATCT-3′
and rev: 5′-ACTCGTCCGGCACGTACAC-3′; DEP-1
fwd: 5′-GCAGTGTTTGGATGTATCTTT-3′ and rev:
5′-CTTCATTATTCTTGGCATCTGT-3′; PTP1B fwd:
5′-CGGGAGGTCAGGGACCTT-3′ and rev: 5′-GGGTC
TTTCCTCTTGTCCATCA-3′.
Immunoblotting
Protein lysates from tissues were prepared using lysis
buffer (150 mM NaCl, 20 mM Tris pH 7.5, 10 mM
EDTA, 30 mM Sodiumpyrophosphat, 0.5% Deoxycholic
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dium vanadate (1 mM), PMSF (1 mM), and protease in-
hibitor cocktail tablets (Roche, Penzberg, Germany) and
quantified using BCA Protein Assay Reagent (Thermo
Fisher Scientific, Bonn, Germany). Precipitation of DEP-
1 in liver protein lysates were performed by incubation
with 40 μl of WGA (wheat germ agglutinin) for 4 hours,
followed by three washing steps with lysis buffer. The
precipitates were dissolved in SDS sample buffer.
Immunoblotting was performed according standard pro-
tocols with primary antibodies (DEP-1 (AF1934 R&D Sys-
tems, Wiesbaden, Germany), anti-phospho Akt (Ser 473),
anti-phospho Akt (Thr 308), anti-pan Akt and anti-
insulin receptor (4B8, Cell Signaling/New England Biolabs,
Frankfurt a.M., Germany), anti-phospho Tyr (PY 99)
(Santa Cruz, CA, USA), anti-phospho Tyr (4G10) and
anti-GAPDH (Millipore, Schwalbach, Germany)). Horserad-
ish peroxidase-conjugated anti-mouse (Dako, Hamburg,
Germany) and anti-rabbit (GE Healthcare, Uppsala,
Sweden) were used as secondary antibodies, and chemilu-
minescence (GE Healthcare, Uppsala, Sweden) served for
visualization. Densitometric analyses were performed
using ImageJ software.
Proximity ligation assay (PLA)
Paraffin-embedded 5 μm liver sections from C57BL/6 mice
were placed on SuperFrost Plus slides (Langenbrinck,
Emmendingen, Germany) and fixed by heating in an incu-
bator for 1.5 h at 60°C. To enable the antibodies to bind to
proteins sections were deparaffinized, rehydrated and
boiled 2 × 5 min in antigen retrieval buffer (citrate pH 6) in
a microwave at 450 W. After cooling down at room
temperature for 30 min the slides were blocked with 5%
BSA in TBS-Tween 0.1% (TBS-T). As primary antibodies
rabbit anti-insulin receptor antibody (ab5500, Abcam,
Cambridge, UK; 1:100) was used together with either a
mouse anti-pY100 antibody (Cell Signaling/New England
Biolabs, Frankfurt a.M., Germany; 1:1200) or a goat anti-
DEP-1 (AF1934, R&D systems, Wiesbaden, Germany;
1:1000) diluted in 5% BSA/TBS-T. The tissue was incu-
bated with both antibodies at 4°C over night. The next day
the tissue was washed 2 × 5 min in TBS-T and incubated
with PLA probes (Olink, Duolink In Situ, Uppsala,
Sweden) anti-rabbit MINUS and either anti-mouse PLUS
or anti-goat PLUS, diluted in 5% BSA/TBS-T, for 1 h at
37°C. Before adding the diluted ligation mixture (Olink,
Duolink In Situ Detection Reagents Orange) and incubat-
ing the tissue sections for 30 min at 37°C the slides were
washed twice in TBS-T for 5 min. Afterwards the slides
were washed 2 × 2 min in 1× Wash Buffer A. The tissue
was then incubated with the diluted amplification mixture
(In Situ Detection Reagents) for amplification by replicat-
ing the DNA circles via rolling circle amplification, for
100 min at 37°C and washed with 1× Wash Buffer B (2 ×10 min) and 0.01× Wash Buffer B (1 min). The stained tis-
sue sections were mounted with Duolink In Situ Mounting
Medium containing DAPI to stain the nuclei and stored at
-20°C.
Pictures of the tissue sections were taken by using an
epifluorescence microscope (Keyence, BZ-9000, Neu-
Isenburg, Germany) with filters for visualization of DAPI
and TRITC and a × 40 objective (CFI Plan Apo), and
rolling circle products (RCPs) were counted. The col-
lected pictures were analyzed using the BZ Analyzer
software from Keyence. For clarity in printing, images
shown where processed using an image editing software
(ImageJ) where a maximum filter was applied to the
PLA channel.
Cell culture and insulin receptor dephosphorylation with
recombinant proteins
AML12 liver cells were purchased from American Type
Culture Collection (ATCC®, Wesel, Germany) and
maintained in DMEM/F12, 10% FBS and 1% penicillin/
streptomycin at 37°C in an atmosphere of 95% air and
5% CO2.
For insulin stimulation cells were starved over night
followed by adding insulin (100 nM) for 10 min. Pre-
pared protein lysates from unstimulated and stimulated
cells were used for immunoprecipitation with insulin re-
ceptor antibody (4B8, Cell Signaling/New England
Biolabs, Frankfurt a.M., Germany), by over night incuba-
tion. Immunoprecipitates were collected by Dynabeads®
Protein G (Invitrogen, Karlsruhe, Germany) for 1 hour.
After washing two times with protein lysis buffer and
once with PTP reaction buffer the precipitates were
resuspended in 40 μl PTP reaction buffer. Recombinant
proteins DEP-1 and PTP1B (Abcam, Cambridge, UK)
were added in a concentration of 1 μg followed by
30 min incubation at 30°C. Control reaction samples
were treated with sodium vanadate 1 mM before recom-
binant proteins were added for dephosphorylation. The
reaction was stopped by SDS sample buffer and boiling
at 95°C for 3 min. Samples were then analyzed by im-
munoblotting with antibodies as indicated.
Statistical analysis
Statistical differences between the groups were deter-
mined using unpaired Student’s t tests. The results are
expressed as mean values ± standard error of the mean,
and statistical significance was designated at P < 0.05.
Additional file
Additional file 1: Figure S1. Analysis of tyrosine phosphorylation levels
in untreated- and ASO treated mice in liver tissue. A: Immunoblotting
analysis of tyrosine phosphorylation was performed in liver tissue derived
from untreated (high-fat diet, HFD) and HFD-fed ASO treated mice
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B: Quantification of phosphotyrosine-containing proteins was done after
normalization to GAPDH and is expressed as arbitrary units.
Densitometric analysis was performed using ImageJ software.
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